Member Info for LovableLumax

Like the science day. We were told in an RNS therapeutic levels of Dox found in biopsies and at the same time point small levels in blood. At the science day they went into a lot more detail on that and all else. They’ll do the same at the AGM. I suspect we will have a DE RNS beforehand but they’ll simply add detail to what’s already in the public domain. Pretty standard stuff.

Material news will be RNS’d beforehand which could be on next DE or otherwise. They’ll add meat to the bones and the update on 6000 and how they’re seeing the trial progress, biopsy data and hopefully cohort 6 underway will be the one.

TR1s incoming due to more shares in issue so dilution.

Only if their interest pushed their total up a %. So if they had 3.4% are they now at 4%+? Given the large number of shares now in issue I doubt many will have gone much higher.

They’ve got cash for a year so will need to accelerate sales (programmatic) to lengthen the cash runway and increase the share price before the raise in Q1 next year. These results were known.

Fair point Davey.

Yep those late large buys yesterday will be hurting. I suspect a sea of red this morning before a recovery. Who knows but they’ll need to announced some new deals soon or it will drift.

*cash burn at £680k/month

They had over £7.52m end of Q1 this year and with the £6.3m raise and cash burn at £6.8m/month they won’t need to think about money until early next year (6 months ahead of running out). That said if they finally accelerate sales and get revenue up with runway increases. They clearly need the programmatic element to significantly increase sales. Working with 50% of the largest advertisers by spend could make this a possibility. Many will have tried to see how it performs and given the results with Kantor surely they’ll want more of it. Not dead yet.

Really exciting and they’re using the drug alongside chemo. Imagine using it with a more effective chemo and one with no or very limited side effects.

Many drugs being trialed are being used in conjunction with chemo which illustrates the potential for preCISION.

MM-

#AVCT acquires Coris Bioconcept for £7.4m cash, bringing in a proprietary range of lateral flow tests, as well as manufacturing capacity.

I suspect this boosts @AvactaDx's 2024 revenue to £30m+, and will drive up the gross margin of the division.

It is now a vertically integrated player, with a key USP of being able to develop and then directly market new (and retrofit existing) products that are powered by Affimers.

A serious entity (almost 150 FTEs) that could command a serious valuation as a standalone business.

With cash of £39m at end March '22 and a Group cash burn rate of ~£18m pa (less positive cash flows to come from the DX Dix going forward), I estimate @avacta's cash runway is reduced to mid summer next year. So no concern on that front. In any event, I'm expecting a major licensing deal for preCISION in the coming months.

Overall, it looks a decent strategic move by AVCT. I would like to see @AvactaDx consolidated now, healthy positive cash flows proved, and then spun off / sold to PE - with cash proceeds used to fund the Golden Goose that is preCISION.

Given cash needed for 6000 etc I can only assume that they have deals waiting to be signed subject to P1a completion and MTD or BSD. Wouldn’t make sense otherwise.

The next one is due end of July. Given the small volume of late very doubtful they would convert early and lose interest as part of the deal. Why would they?

A positive next RNS and they may well do as will be able to sell into which I think is good as that would be number 4 and 20% of the debt.

The clinicians and investigators will likely know after a handful of patients and as mentioned from circa 30 days and really pronounced from 60 days. I don’t expect recruitment to be an issue with the number of sites planned so hopefully we reach MTD or BSD soon to get P1b set up and started.

a **** poor article. he’s so poorly researched it’s unprofessional. waste of time.

BV it follows P1 was dosed and 3 weeks later would receive their second dose while P2/3 would have their first doses and 3 weeks after their second followed by 72 hours observation. Look at the trial design.

Commenting on cohorts OTT and smacks of desperation. We will have an update at the AGM if not before re next cohort.

Not until nee shares are admitted.

Money look at the Oct RNS. DYOR. It’s simple.

This is the key to accelerate sales/revenue they need scale and programmatic.

The Company is being told by supply partners and demand partners that they wish to trade in-content advertising programmatically and that volume of trade will substantially improve once the Company fully rolls out a programmatic sales solution.